清瘀温通方治疗子宫腺肌病痛经的临床疗效  

Clinical efficacy of Qingyu Wentong Formula in the treatment of dysmenorrhea due to adenomyosis

作　　者：夏馨 杜尘 庄梦斐[2] 王唯迪[2] 曹阳[2] 张婷婷[2] XIA Xin;DU Chen;ZHUANG Mengfei;WANG Weidi;CAO Yang;ZHANG TingTing(Jing'an district hospital of traditional chinese medicine,shanghai 200047,china;Yueyang hospital of integrated traditional chinese and western medicine,shanghai university of traditional chinese medicine,shanghai 200437,china)

机构地区：[1]上海市静安区中医医院,上海200047 [2]上海中医药大学附属岳阳中西医结合医院,上海200437

出　　处：《上海中医药大学学报》2021年第6期37-41,共5页Academic Journal of Shanghai University of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(82074475);上海市科委科研计划项目(18401972000);上海市“十三五”临床重点专科建设项目(shslczdzk04501);上海市静安区卫计委科研项目(2019ZY04)。

摘　　要：目的:观察清瘀温通方治疗子宫腺肌病痛经患者的临床疗效及对相关炎症因子的影响。方法:纳入子宫腺肌病痛经患者62例,采用随机数字表分为治疗组32例和对照组30例。治疗组患者给予清瘀温通方口服治疗,对照组患者给予散结镇痛胶囊口服治疗,治疗周期为3个月经周期。评价并比较两组患者的痛经改善疗效;采用视觉模拟评分法(VAS)评价患者的痛经疼痛程度;检测两组患者的血清糖类抗原125(CA125)、超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、单核细胞趋化蛋白-1(MCP-1)的水平。结果:(1)治疗后,治疗组患者的痛经改善疗效总有效率为84.38%,对照组为60.00%,治疗组的疗效优于对照组(P<0.05)。(2)治疗后,两组患者的痛经疼痛VAS评分较治疗前均显著下降(P<0.01),但两组间评分比较,差异无统计学意义(P>0.05)。(3)治疗后,两组患者的hs-CRP、IL-6、MCP-1水平较治疗前均降低(P<0.05),治疗组患者的CA125水平较治疗前亦降低(P<0.05),且治疗组患者的CA125、hs-CRP、IL-6、MCP-1水平低于对照组(P<0.05)。结论:清瘀温通方可明显减轻子宫腺肌病患者的痛经症状,其机制可能与抑制血清促炎细胞因子的产生、减轻炎症反应及改善子宫内环境微炎症状态有关。Objective: To observe the clinical efficacy of Qingyu Wentong Formula in treating patients with dysmenorrhea due to adenomyosis and its influence on the related inflammatory factors. Methods: A total of 62 patients with dysmenorrhea due to adenomyosis were included and divided into the treatment group(32 cases) and control group(30 cases) by random number table. The patients in the treatment group were orally treated with Qingyu Wentong Formula, and the patients in the control group were orally treated with Sanjie Zhentong Capsule. The treatment course was 3 menstrual cycles. The improvement efficacy on dysmenorrhea in both groups was evaluated and compared, the pain degree of dysmenorrhea was evaluated by visual analogue scale(VAS), and the serum levels of carbohydrate antigen 125(CA125), high sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6) and monocyte chemoattractant protein-1(MCP-1) were detected. Results:(1)After treatment, the total effective rate of dysmenorrhea improvement was 84.38% in the treatment group and 60.00% in the control group, and the efficacy of the treatment group was better than that of the control group(P<0.05).(2)After treatment, the VAS score of dysmenorrhea pain in both groups was significantl decreased compared with that before treatment(P<0.01), but there was no statistically significant difference on the score between the two groups(P>0.05).(3)After treatment, the levels of hs-CRP, IL-6 and MCP-1 in both groups were decreased compared with those before treatment(P<0.05), the level of CA125 in the treatment group was also decreased compared with that before treatment(P<0.05), and the levels of CA125, hs-CRP, IL-6 and MCP-1 in the treatment group were lower than those in the control group(P<0.05). Conclusion: Qingyu Wentong Formula can significantly reduce the symptoms of dysmenorrhea in patients with adenomyosis, and its mechanisms may be related to inhibiting the production of serum proinflammatory cytokines, reducing inflammatory reaction and improving the micro-inflamma

关 键 词：子宫腺肌病 痛经 清瘀温通方 炎症因子 

分 类 号：R271.113[医药卫生—中医妇科学]